Embattled genetic testing company 23andMe said on Tuesday that it’s started exploring strategic alternatives for a second time, which could include a sale of the company or its assets, a restructuring or a business combination. The stock, which lost 82% of its value last year, fell 10% in extended trading and was briefly halted. The announcement coincided with the release of 23andMe’s third-quarter results. Revenue in the company’s consumer services business dropped 8% to $39.6 million from $42.9 million in the same period last year. The company said it will “need additional liquidity” to fund its operations, and it is looking to raise capital.
Read the full article: 23andMe Is Exploring Strategic Alternatives, Looking to Raise Capital //
Source: https://www.cnbc.com/2025/01/28/23andme-is-exploring-strategic-alternatives-looking-to-raise-capital.html